Amgen Inc.

Merck Sharp + Dohme Corp.

Kevin Gorski

Andrew A Welcher

Michael J Boedigheimer

Jane R Parnes

Jeannette Bigler

Abraham Antonio Anderson

Jennifer Lorraine Gansert

Jeanette Bigler

Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.

Biomarkers for cancer therapeutics

The present disclosure relates to a method for detecting T helper cell or CTL subpopulations in a subject affected by disease or disorder having an immune component. The methods are also useful for determining efficacy of a treatment of the disease or disorder by detecting skewing of the T helper cells and CTLs in a therapeutic or adverse direction.

Assay for detecting TH1 and TH2 cell populations

Assay for detecting Th1 and Th2 cell populations

Growing community of inventors

Newbury Park, CA, United States of America

Kevin Gorski